INTELLIGENT BIO SOLUTIONS INC
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
INBS$2.29+16.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Shareholders’ Equity
| Additional · Other · Non- · Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Common stock · Treasury stock · paid in · Accumulated · comprehensive · controlling · shareholders’ | |||||||||
| Shares | Amount | Shares | Amount | capital | deficit | income / (loss) | interest | equity | |
| Balance, June 30, 2024* | 3,456,000 | $34,557 | (116) | $(1) | $60,971,740 | $(51,964,332) | $(712,614) | $(146,159) | $8,183,191 |
| Issuance of common stock upon cashless exercise of warrants | 793,930 | 7,939 | - | - | - | - | - | - | 7,939 |
| Stock awards issued to employees | 99,500 | 995 | - | - | 189,050 | - | - | - | 190,045 |
| Issuance of restricted stock to vendors | 11,162 | 112 | - | - | 11,888 | - | - | - | 12,000 |
| Issuance of common stock, net of issuance costs | 17,167 | 172 | - | - | 34,339 | - | - | - | 34,511 |
| Foreign currency translation gain | - | - | - | - | - | - | 216,355 | - | 216,355 |
| Net loss | - | - | - | - | - | (2,685,633) | - | (9,166) | (2,694,799) |
| Balance, September 30, 2024* | 4,377,759 | $43,775 | (116) | $(1) | $61,207,017 | $(54,649,965) | $(496,259) | $(155,325) | $5,949,242 |
| Additional · Other · Non- · Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Common stock · Treasury stock · paid in · Accumulated · comprehensive · controlling · shareholders’ | |||||||||
| Shares | Amount | Shares | Amount | capital | deficit | Income/ (loss) | interest | equity | |
| Balance, June 30, 2023* | 194,200 | $1,942 | (116) | $(1) | $46,180,112 | $(41,807,573) | $(575,496) | $(111,986) | $3,686,998 |
| Foreign currency translation loss | - | - | - | - | - | - | (18,016) | - | (18,016) |
| Net loss | - | - | - | - | - | (2,425,204) | - | (7,220) | (2,432,424) |
| Balance, September 30, 2023* | 194,200 | $1,942 | (116) | $(1) | $46,180,112 | $(44,232,777) | $(593,512) | $(119,206) | $1,236,558 |
| * | Common stock has been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, throughout the condensed consolidated financial statements unless otherwise stated. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.